340B covered entities in the prime vendor program (PVP) spent nearly $44 billion on 340B drugs in 2021—up from $6.6 [...] …
Articles by : Shannon Young, Associate Editor/Senior Writer
A national hospital trade group urged federal officials Monday to investigate whether five major drugmakers engaged in anticompetitive practices while [...] …
A South Carolina Republican U.S. House lawmaker recently honored the life and legacy of Sue Veer, a nationally recognized leader [...] …
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Washington D.C.’s most powerful drug industry trade group this week ramped up its attacks on the 340B program, launching what’s [...] …
A New Jersey-based pharmaceutical manufacturer recently became the 39th drugmaker to enact 340B contract pharmacy restrictions. Mitsubishi Tanabe Pharma America [...] …
The 340B program continued to garner strong lobbying attention on Capitol Hill this spring, despite Congress’ focus on a GOP-backed [...] …
Several drugmakers recently announced refunds to 340B covered entities that purchased certain medications between 2019 and 2025, following recalculations of [...] …
An Indiana-based pharmaceutical giant recently announced that it’s working to align its U.S. drug prices with those paid by other [...] …
A Swiss pharmaceutical giant this week announced new 340B contract pharmacy restriction exemptions for two states that recently enacted contract [...] …